Decoding FGFR inhibitor sensitivity in cholangiocarcinoma with interpretable machine learning and cross-platform pharmacogenomic validation
Artículo
Material complementario disponible
Artículo
DOAJ
BackgroundFibroblast growth factor receptor (FGFR) inhibitors (FGFRis) benefit selected cholangiocarcinoma (CHOL) patients, yet responses remain heterogeneous and are not fully explained by canonical FGFR alterations. Cl...
LCC LCC:Therapeutics. PharmacologyIdioma eng
Material complementario disponibleEl enlace apunta a material asociado, anexos, tablas, datos o página complementaria. No se marca como libro/texto completo.
Material complementario